SCHEMBL3847559

SCHEMBL3847559

Cc1ccc2c(c1)CC(=O)CC2

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.54
METAP1 P53582 2/20 0.47
SRD5A1 P18405 6/20 0.42
PARP10 Q53GL7 2/20 0.42
PARP11 Q9NR21 1/20 0.42
PARP1 P09874 1/20 0.42
ALDH1A1 P00352 2/20 0.41
KDM4E B2RXH2 1/20 0.41
POLB P06746 1/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 1/20 0.41
PKM P14618 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CYP3A4 P08684 3/20 0.40
NOTUM Q6P988 1/20 0.40
CYP1A2 P05177 2/20 0.39
CYP2C9 P11712 2/20 0.39
CYP11B1 P15538 2/20 0.39
CYP11B2 P19099 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1701852 0.92 CYP2A6 (0.54) CYP2A6METAP1SRD5A1PARP10PARP11
SCHEMBL5146565 0.88 METAP1 (0.44) CYP2A6METAP1PARP10PARP11PARP1
SCHEMBL17037968 0.88 METAP1 (0.44) CYP2A6METAP1SRD5A1PARP10PARP11
SCHEMBL10177007 0.87 METAP1 (0.46) CYP2A6METAP1SRD5A1PARP10PARP11
SCHEMBL6584911 0.85 METAP1 (0.52) CYP2A6METAP1PARP10PARP11PARP1
SCHEMBL6905898 0.84 ALDH1A1 (0.47) CYP2A6METAP1SRD5A1PARP10PARP11
SCHEMBL27844103 0.81 CYP2A6 (0.46) CYP2A6METAP1SRD5A1PARP10PARP11
SCHEMBL27861246 0.81 CYP2A6 (0.46) CYP2A6METAP1SRD5A1PARP10PARP11
SCHEMBL12430501 0.80 METAP1 (0.44) CYP2A6METAP1PARP10PARP11PARP1
SCHEMBL5929505 0.78 CYP2A6 (0.58) CYP2A6METAP1PARP10PARP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230227472-A1 FUSED PYRIDONE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD (CN) 2023-07-20 US disclosed
US-20230128402-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF THE TRUSTEES OF PRINCETON UNIVERSITY 2023-04-27 US disclosed
US-20180127374-A1 BENZOMORPHAN COMPOUNDS AS OPIOID RECEPTORS MODULATORS PURDUE PHARMA LP (US) 2018-05-10 US disclosed
WO-2018068357-A1 NOVEL SIRT2 PROTEIN INHIBITOR AND PHARMACEUTICAL USE THEREOF 西华大学 2018-04-19 WO disclosed
US-20170290816-A1 BENZOMORPHAN ANALOGS AND THE USE THEREOF PURDUE PHARMA L.P. (US) 2017-10-12 US disclosed
EP-2860176-B1 HETEROCYCLIC GROUP CONTAINED AMINO-METHANOL DERIVATIVE, AND SALT, SYNTHETIC METHOD AND USE THEREOF BEIJING FORELAND BIOPHARMA CO LTD (CN) 2017-09-27 EP disclosed
US-20150210646-A1 BENZOMORPHAN COMPOUNDS AS OPIOID RECEPTORS MODULATORS PURDUE PHARMA L.P. 2015-07-30 US disclosed
US-8524738-B2 Quinolinones and quinoxalinones as antibacterial composition TOYAMA CHEMICAL CO., LTD. (JP) 2013-09-03 US disclosed
US-8436016-B2 Fused heterocyclic M1 receptor positive allosteric modulators Merck, Sharp & Dohme, Corp. 2013-05-07 US disclosed
US-20120214990-A1 QUINOLINONES AND QUINOXALINONES AS ANTIBACTERIAL COMPOSITION TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-08-23 US disclosed
US-20070225528-A1 Process for Producing Optically Active Alcohol NAGOYA INDUSTRIAL SCIENCE RESEARCH CENTER (JP) 2007-09-27 US disclosed
CN-101018766-A Process for preparing substituted tetralin and substituted indane derivatives JANSSEN PHARMACEUTICA NV (BE) 2007-08-15 CN disclosed
EP-1745016-A1 PROCESS FOR THE PREPARATION OF SUBSTITUTED TETRALIN AND SUBSTITUTED INDANE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2007-01-24 EP disclosed
EP-1741693-A1 PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE ALCOHOLS Nagoya Industrial Science Research Institute (JP) 2007-01-10 EP disclosed
WO-2005105737-A1 PROCESS FOR THE PREPARATION OF SUBSTITUTED TETRALIN AND SUBSTITUTED INDANE DERIVATIVES JANSSEN PHARMACEUTICA, N.V. (BE) 2005-11-10 WO disclosed
US-20050240049-A1 Process for the preparation of substituted tetralin and substituted indane derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2005-10-27 US disclosed
EP-0535034-B1 PHARMACEUTICALLY ACTIVE BENZOQUINAZOLINE COMPOUNDS WELLCOME FOUND (GB) 2002-08-14 EP disclosed
EP-0635497-B1 Benzospiroalkene derivatives, process for their preparation and pharmaceutical compostions containing them ADIR (FR) 1998-05-20 EP disclosed
US-5436261-A Adrenergic agonists ADIR ET COMPAGNIE (FR) 1995-07-25 US disclosed
EP-0635497-A2 Benzospiroalkene derivatives, process for their preparation and pharmaceutical compostions containing them ADIR ET COMPAGNIE (FR) 1995-01-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225528-A1 Process for Producing Optically Active Alcohol ADH1C, ADH1A, ADH5 CYP2A6 1034/4885METAP1 4453/4885SRD5A1 19/4885
US-20150210646-A1 BENZOMORPHAN COMPOUNDS AS OPIOID RECEPTORS MODULATORS OPRL1, OPRM1, OPRD1 CYP2A6 555/4885METAP1 1477/4885SRD5A1 693/4885
US-20180127374-A1 BENZOMORPHAN COMPOUNDS AS OPIOID RECEPTORS MODULATORS OPRL1, OPRM1, OPRD1 CYP2A6 555/4885METAP1 1477/4885SRD5A1 693/4885
US-20230227472-A1 FUSED PYRIDONE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF KRAS, NRAS, WEE1 CYP2A6 607/4885METAP1 2788/4885SRD5A1 1485/4885
US-20120214990-A1 QUINOLINONES AND QUINOXALINONES AS ANTIBACTERIAL COMPOSITION NQO2, ASNS, NDUFS1 CYP2A6 1680/4885METAP1 3082/4885SRD5A1 3429/4885
US-20170290816-A1 BENZOMORPHAN ANALOGS AND THE USE THEREOF OPRL1, OPRK1, OPRD1 CYP2A6 173/4885METAP1 3392/4885SRD5A1 739/4885
US-20050240049-A1 Process for the preparation of substituted tetralin and substituted indane derivatives TDO2, TTI2, ITPA CYP2A6 973/4885METAP1 2595/4885SRD5A1 1611/4885
US-20230128402-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF PAH, ALDH2, IDH2 CYP2A6 1025/4885METAP1 1926/4885SRD5A1 478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.